An update on small molecule compounds targeting synthetic lethality for cancer therapy
- 2 September 2024
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 278, 116804
Abstract
No abstract availableKeywords
This publication has 196 references indexed in Scilit:
- The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer2023
- WRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI)2023
- Development of covalent inhibitors: Principle, design, and application in cancerMedComm – Oncology, 2023
- Design, Synthesis, and Biological Evaluation of 2‐Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) InhibitorsChemMedChem, 2023
- Targeting DNA repair pathway in cancer: Mechanisms and clinical applicationMedcomm, 2021
- Synthesis and evaluation of 2‐(4‐[4‐acetylpiperazine‐1‐carbonyl] phenyl)‐1H‐benzo[d]imidazole‐4‐carboxamide derivatives as potential PARP‐1 inhibitors and preliminary study on structure‐activity relationshipDrug Development Research, 2021
- Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid LeukemiaChemMedChem, 2021
- Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing LymphomaTargeted Oncology, 2019
- RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesInternational Journal of Cancer, 2017
- Structure‐activity relationship of the peptide binding‐motif mediating the BRCA2:RAD51 protein–protein interactionFEBS Letters, 2016